Skip to main content
Erschienen in: Pituitary 4/2017

09.03.2017

Follow-up intervals in patients with Cushing’s disease: recommendations from a panel of experienced pituitary clinicians

verfasst von: Eliza B. Geer, Alejandro Ayala, Vivien Bonert, John D. Carmichael, Murray B. Gordon, Laurence Katznelson, Ekaterina Manuylova, Ismat Shafiq, Vijaya Surampudi, Ronald S. Swerdloff, Michael S. Broder, Dasha Cherepanov, Marianne Eagan, Jackie Lee, Qayyim Said, Maureen P. Neary, Beverly M. K. Biller

Erschienen in: Pituitary | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Follow-up guidelines are needed to assess quality of care and to ensure best long-term outcomes for patients with Cushing’s disease (CD). The purpose of this study was to assess agreement by experts on recommended follow-up intervals for CD patients at different phases in their treatment course.

Methods

The RAND/UCLA modified Delphi process was used to assess expert consensus. Eleven clinicians who regularly manage CD patients rated 79 hypothetical patient scenarios before and after (“second round”) an in-person panel discussion to clarify definitions. Scenarios described CD patients at various time points after treatment. For each scenario, panelists recommended follow-up intervals in weeks. Panel consensus was assigned as follows: “agreement” if no more than two responses were outside a 2 week window around the median response; “disagreement” if more than two responses were outside a 2 week window around the median response. Recommendations were developed based on second round results.

Results

Panel agreement was 65.9% before and 88.6% after the in-person discussion. The panel recommended follow-up within 8 weeks for patients in remission on glucocorticoid replacement and within 1 year of surgery; within 4 weeks for patients with uncontrolled persistent or recurrent disease; within 8–24 weeks in post-radiotherapy patients controlled on medical therapy; and within 24 weeks in asymptomatic patients with stable plasma ACTH concentrations after bilateral adrenalectomy.

Conclusions

With a high level of consensus using the Delphi process, panelists recommended regular follow-up in most patient scenarios for this chronic condition. These recommendations may be useful for assessment of CD care both in research and clinical practice.
Literatur
1.
Zurück zum Zitat Newell-Price J, Bertagna X, Grossman AB, Nieman LK (2006) Cushing’s syndrome. The Lancet 367(9522):1605–1617CrossRef Newell-Price J, Bertagna X, Grossman AB, Nieman LK (2006) Cushing’s syndrome. The Lancet 367(9522):1605–1617CrossRef
2.
Zurück zum Zitat Nieman LK, Biller BMK., Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM (2008) The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:1526–1540CrossRefPubMedPubMedCentral Nieman LK, Biller BMK., Findling JW, Newell-Price J, Savage MO, Stewart PM, Montori VM (2008) The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:1526–1540CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Swearingen B, Wu N, Chen SY, Pulgar S, Biller BM (2011) Health care resource use and costs among patients with Cushing disease. Endocr Pract 17(5):681–690CrossRefPubMed Swearingen B, Wu N, Chen SY, Pulgar S, Biller BM (2011) Health care resource use and costs among patients with Cushing disease. Endocr Pract 17(5):681–690CrossRefPubMed
4.
Zurück zum Zitat Broder MS, Neary MP, Chang E, Cherepanov D, Ludlam WH (2015) Incidence of Cushing’s syndrome and Cushing’s disease in commercially-insured patients <65 years old in the United States. Pituitary 18(3):283–289CrossRefPubMed Broder MS, Neary MP, Chang E, Cherepanov D, Ludlam WH (2015) Incidence of Cushing’s syndrome and Cushing’s disease in commercially-insured patients <65 years old in the United States. Pituitary 18(3):283–289CrossRefPubMed
5.
Zurück zum Zitat Extabe J, Vazquez JA (1994) Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol 40:479–484CrossRef Extabe J, Vazquez JA (1994) Morbidity and mortality in Cushing’s disease: an epidemiological approach. Clin Endocrinol 40:479–484CrossRef
6.
Zurück zum Zitat Feelders RA, Pulgar SJ, Kempel A, Pereira AM (2012) The burden of Cushing’s disease: clinical and health-related quality of life aspects. Eur J Endocrinol 167(3):311–326CrossRefPubMed Feelders RA, Pulgar SJ, Kempel A, Pereira AM (2012) The burden of Cushing’s disease: clinical and health-related quality of life aspects. Eur J Endocrinol 167(3):311–326CrossRefPubMed
7.
Zurück zum Zitat Lindholm J, Juul S, Jørgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jørgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J (2001) Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 86(1):117–123PubMed Lindholm J, Juul S, Jørgensen JO, Astrup J, Bjerre P, Feldt-Rasmussen U, Hagen C, Jørgensen J, Kosteljanetz M, Kristensen L, Laurberg P, Schmidt K, Weeke J (2001) Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 86(1):117–123PubMed
8.
Zurück zum Zitat Ayala A, Manzano AJ (2014) Detection of recurrent Cushing’s disease: proposal for standardized patient monitoring following transsphenoidal surgery. J Neurooncol 119(2):235–242CrossRefPubMedPubMedCentral Ayala A, Manzano AJ (2014) Detection of recurrent Cushing’s disease: proposal for standardized patient monitoring following transsphenoidal surgery. J Neurooncol 119(2):235–242CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JH, Romijn JA (2007) Mortality in patients treated for Cushing’s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 92(3):976–981CrossRefPubMed Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JH, Romijn JA (2007) Mortality in patients treated for Cushing’s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 92(3):976–981CrossRefPubMed
10.
Zurück zum Zitat Colao A, Boscaro M, Ferone D, Casanueva FF (2014) Managing Cushing’s disease: the state of the art. Endocrine 47(1):9–20CrossRefPubMed Colao A, Boscaro M, Ferone D, Casanueva FF (2014) Managing Cushing’s disease: the state of the art. Endocrine 47(1):9–20CrossRefPubMed
12.
Zurück zum Zitat Monteith SJ, Starke RM, Jane JA Jr, Oldfield EH (2012) Use of the histological pseudocapsule in surgery for Cushing disease: rapid postoperative cortisol decline predicting complete tumor resection. J Neurosurg 116:721–727CrossRefPubMed Monteith SJ, Starke RM, Jane JA Jr, Oldfield EH (2012) Use of the histological pseudocapsule in surgery for Cushing disease: rapid postoperative cortisol decline predicting complete tumor resection. J Neurosurg 116:721–727CrossRefPubMed
13.
Zurück zum Zitat Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A, Endocrine Society (2015) Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 100(8):2807–2831CrossRefPubMedPubMedCentral Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A, Endocrine Society (2015) Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 100(8):2807–2831CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93(7):2454–2462CrossRefPubMedPubMedCentral Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93(7):2454–2462CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lazaro P, van het Loo M, McDonnell J, Paul Vader J, Kahan JP (2001) The RAND/UCLA appropriateness method user’s manual. No. RAND/MR-1269-DG-XII/RE. RAND Corp, Santa Monica Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lazaro P, van het Loo M, McDonnell J, Paul Vader J, Kahan JP (2001) The RAND/UCLA appropriateness method user’s manual. No. RAND/MR-1269-DG-XII/RE. RAND Corp, Santa Monica
17.
Zurück zum Zitat Shekelle PG, Kahan JP, Bernstein SJ, Leape LL, Kamberg CJ, Park RE (1998) The reproducibility of a method to identify the overuse and underuse of medical procedures. N Engl J Med 338(26):1888–1895CrossRefPubMed Shekelle PG, Kahan JP, Bernstein SJ, Leape LL, Kamberg CJ, Park RE (1998) The reproducibility of a method to identify the overuse and underuse of medical procedures. N Engl J Med 338(26):1888–1895CrossRefPubMed
18.
Zurück zum Zitat Shekelle PG, Park RE, Kahan JP, Leape LL, Kamberg CJ, Bernstein SJ (2001) Sensitivity and specificity of the RAND/UCLA appropriateness method to identify the overuse and under use of coronary revascularization and hysterectomy. J Clin Epidemiol 54:1004–1010CrossRefPubMed Shekelle PG, Park RE, Kahan JP, Leape LL, Kamberg CJ, Bernstein SJ (2001) Sensitivity and specificity of the RAND/UCLA appropriateness method to identify the overuse and under use of coronary revascularization and hysterectomy. J Clin Epidemiol 54:1004–1010CrossRefPubMed
19.
Zurück zum Zitat Appropriateness of Treating Glaucoma Suspects RAND Study Group (ATGSRSG) (2009) For which glaucoma suspects is it appropriate to initiate treatment? Ophthalmology 116:710–716CrossRef Appropriateness of Treating Glaucoma Suspects RAND Study Group (ATGSRSG) (2009) For which glaucoma suspects is it appropriate to initiate treatment? Ophthalmology 116:710–716CrossRef
20.
Zurück zum Zitat Broder MS, Kanouse DE, Mittman BS, Bernstein SJ (2000) The appropriateness of recommendations for hysterectomy. Obstet Gynecol 95(2):199–205PubMed Broder MS, Kanouse DE, Mittman BS, Bernstein SJ (2000) The appropriateness of recommendations for hysterectomy. Obstet Gynecol 95(2):199–205PubMed
21.
Zurück zum Zitat Fraser IS, Critchley HO, Munro MG, Broder M (2007) Writing group for this menstrual agreement process: a process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril 87(3):466–476, Erratum in: Fertil Steril 88(2):538 Fraser IS, Critchley HO, Munro MG, Broder M (2007) Writing group for this menstrual agreement process: a process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril 87(3):466–476, Erratum in: Fertil Steril 88(2):538
22.
Zurück zum Zitat Hanley D, Gorelick PB, Elliott WJ, Broder MS, Saver JL, Kidwell CS, Fagan SC, Wilson A, Lennihan L, Schwer WA, Rubenstein LZ, Crowell RM, Haines SJ, Lopez CC, Zorowitz R, Dubois RW (2004) Determining the appropriateness of selected surgical and medical management options in recurrent stroke prevention: a guideline for primary care physicians from the National Stroke Association work group on recurrent stroke prevention. J Stroke Cerebrovasc Dis 13(5):196–207CrossRefPubMed Hanley D, Gorelick PB, Elliott WJ, Broder MS, Saver JL, Kidwell CS, Fagan SC, Wilson A, Lennihan L, Schwer WA, Rubenstein LZ, Crowell RM, Haines SJ, Lopez CC, Zorowitz R, Dubois RW (2004) Determining the appropriateness of selected surgical and medical management options in recurrent stroke prevention: a guideline for primary care physicians from the National Stroke Association work group on recurrent stroke prevention. J Stroke Cerebrovasc Dis 13(5):196–207CrossRefPubMed
23.
Zurück zum Zitat Hemingway H, Crook AM, Feder G, Banerjee S, Dawson JR, Magee P, Philpott S, Sanders J, Wood A, Timmis AD (2001) Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization. N Engl J Med 344:645–654CrossRefPubMed Hemingway H, Crook AM, Feder G, Banerjee S, Dawson JR, Magee P, Philpott S, Sanders J, Wood A, Timmis AD (2001) Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization. N Engl J Med 344:645–654CrossRefPubMed
24.
Zurück zum Zitat Strosberg JR, Fisher GA, Benson AB, Anthony LB, Arslan B, Gibbs JF, Greeno E, Iyer RV, Kim MK, Maples WJ, Philip PA, Wolin EM, Cherepanov D, Broder MS (2015) Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors. World J Gastroenterol 21(8):2450–2459CrossRefPubMedPubMedCentral Strosberg JR, Fisher GA, Benson AB, Anthony LB, Arslan B, Gibbs JF, Greeno E, Iyer RV, Kim MK, Maples WJ, Philip PA, Wolin EM, Cherepanov D, Broder MS (2015) Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors. World J Gastroenterol 21(8):2450–2459CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Strosberg JR, Fisher GA, Benson AB, Malin JL, GEPNET Treatment Consensus Panel, Cherepanov D, Broder MS, Anthony LB, Arslan B, Fisher GA, Gibbs JF, Greeno E, Iyer RV, Kim MK, Maples W, Philip PA, Strosberg J, Wolin EM (2013) Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process. Pancreas 42(3):397–404CrossRefPubMed Strosberg JR, Fisher GA, Benson AB, Malin JL, GEPNET Treatment Consensus Panel, Cherepanov D, Broder MS, Anthony LB, Arslan B, Fisher GA, Gibbs JF, Greeno E, Iyer RV, Kim MK, Maples W, Philip PA, Strosberg J, Wolin EM (2013) Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process. Pancreas 42(3):397–404CrossRefPubMed
26.
Zurück zum Zitat Kravitz RL, Laouri M, Kahan JP, Guzy P, Sherman T, Hilborne L, Brook RH (1995) Validity of criteria used for detecting underuse of coronary revascularization. JAMA 274:632–648CrossRefPubMed Kravitz RL, Laouri M, Kahan JP, Guzy P, Sherman T, Hilborne L, Brook RH (1995) Validity of criteria used for detecting underuse of coronary revascularization. JAMA 274:632–648CrossRefPubMed
27.
Zurück zum Zitat Shekelle PG, Chassin MR, Park RE (1998) Assessing the predictive validity of the RAND/UCLA appropriateness method criteria for performing carotid endarterectomy. Int J Technol Assess Health Care 14(4):707–727CrossRefPubMed Shekelle PG, Chassin MR, Park RE (1998) Assessing the predictive validity of the RAND/UCLA appropriateness method criteria for performing carotid endarterectomy. Int J Technol Assess Health Care 14(4):707–727CrossRefPubMed
Metadaten
Titel
Follow-up intervals in patients with Cushing’s disease: recommendations from a panel of experienced pituitary clinicians
verfasst von
Eliza B. Geer
Alejandro Ayala
Vivien Bonert
John D. Carmichael
Murray B. Gordon
Laurence Katznelson
Ekaterina Manuylova
Ismat Shafiq
Vijaya Surampudi
Ronald S. Swerdloff
Michael S. Broder
Dasha Cherepanov
Marianne Eagan
Jackie Lee
Qayyim Said
Maureen P. Neary
Beverly M. K. Biller
Publikationsdatum
09.03.2017
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 4/2017
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-017-0801-2

Weitere Artikel der Ausgabe 4/2017

Pituitary 4/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.